Serum p53 autoantibodies in the follow-up of head and neck cancer patients

Oncology

Volumn 59, Issue 1, 2000, Pages 31-35

  Gottschlich, Stefan ^a   Maune, S ^b   Maass, J D ^b   Gorogh T ^b   Hoffmann, M ^b   Hoffmann Fazel, A ^b   Meyer, J ^b   Werner, J A ^b   Rudert, H ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b NONE

Author keywords

Autoantibodies; Follow up; Head and neck cancer; P53; Squamous cell carcinoma

Indexed keywords

AUTOANTIBODY; PROTEIN P53;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CANCER PATIENT; FOLLOW UP; HEAD CANCER; HUMAN; NECK CANCER; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033947574     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012134     Document Type: Article

References (29)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253:49-53.
2. Lane DP: p53, guardian of the genome. Nature 1992;358:15-16.
3. Levine AJ: The p53 protein and its interaction with the oncogene products of the small DNA tumor viruses. Virology 1990;177:419-426.
4. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245.
5. Crawford LV, Pim DC, Bullbrook RD: Detection of antibodies against the cellular protein p53 in sera of patients with breast cancer. Int J Cancer 1982;30:403-408.
6. Maass JD, Gottschlich S, Lippert BM, Niemann AM, Görögh T, Werner JA: Antikörperbildung gegen das zelluläre Protein p53 bei Patienten mit Plattenepithelkaranomen der oberen Luft-und Speisewege. Laryngorhinoolologie 1996;75:53-56.
7. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA, Bunting PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480-487.
8. Marxsen J, Schmiegel W, Roeder C, Harder R, Juhl H, Henne-Bruns D, Kremer B, Kalthoff H: Detection of the p53-antibody response in malignant and benign pancreatic disease. Br J Cancer 1994;70:1031-1034.
9. Kovacs B, Patel A, Hershey JN, Dennis GJ, Kirschfink N, Tsokos GC: Antibodies against p53 in sera from patients with systemic lupus crythematosus and other rheumatic diseases. Arthritis Rheum 1997;40:980-982.
10. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992;52:4168-4174.
11. Schlichtholz B, Legros Y, Gillet D, Guillard C, Marty M, Lane D, Calvo F, Soussi T: The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992;52:6380-6384.
12. Labrecque AJ, Naor N, Thomson G, Matlashewski G: Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993; 53:3468-3471.
13. Lubin R, Schlichtholz B, Bengoufa D, Zaleman G, Trédaniel J, Hirsch A, Caron de Fromentel C, Preudhomme C, Fenaux P, Fournier G, Mangin P, Laurent-Puig P, Pelletier G, Schlumberger M, Desgrandchamps F, Leduc A, Peyrat JP, Janin N, Bressac B, Soussi T: Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: Distribution on primary structure and exposure on protein surface. Cancer Res 1992;53: 5872-5876.
14. Houbiers JGA, van der Burg SH, van de Watering LMG, Tollenaar RA, Brand A, van de Felde, Melief CJ: Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 1995;72:637-641.
15. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T: Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995;345:621-622.
16. Werner JA, Gottschlich S, Folz BJ, Görögh T, Lippert BM, Maass JD, Rudert H: p53 serum antibodies as prognostic indicator in head and neck cancer. Cancer Immunol Immunother 1997;44:112-116.
17. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, Talbot M, Marandas P, Schwaab G, Wibault P, Luboinski P, Eschwege F, Soussi T: Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1228-1233.
18. Lubin R, Zalcman G, Bouchet L, Trédaniel J, Legros Y, Cazals D, Hirsh A, Soussi T: Serum p53 antibodies as early markers of lung cancer. Nat Med 1995;1:701-702.
19. Davidoff AM, Iglehart JD, Marks JR: Immune response to p53 is dependent upon p53/HSP70 complexes. Proc Natl Acad Sci USA 1992;89: 3439-3442.
20. Gottschlich S, Maass JD, Görögh T, Lippert BM, Werner JA: Die Immunantwort gegen p53 bei Patienten mit Plattenepithelkarzinomen der oberen Luft-und Speisewege ist unabhängig von der p53-Punktmutation. Laryngorhinootologie 1996;75:301-305.
21. Mitsudomi T, Suzuki S, Yatabe Y, Nishio M, Kuwabara M, Gotoh K, Hatooka S, Shinoda M, Suyama M, Ogawa M, Takahashi T, Ariyoshi Y, Takahashi T: Clinical implications of p53 autoantibodies in the sera of patients with non small cell lung cancer. J Natl Cancer Inst 1998;21:1563-1568.
22. Willsher PC, Pinder SE, Robertson L, Nicholson RI, Ellis IO, Bell JA, Blamey RW, Green JA, Robertson JF: The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res 1996;16:927-930.
23. Gadducci A, Ferdeghini M, Buttita F, Cosio S, Fanucchu A, Annichiarico C, Genazzini AR: Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. Anticancer Res 1998;18:3763-3765.
24. Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis EP: Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer 1996;78: 2146-2152.
25. Zalcman G, Schlichtholz B, Trédaniel J, Urban T, Lubin R, Dubois I, Milleron B, Hirsch A, Soussi T: Monitoring p53 autoantibodies in lung cancer during therapy: Relationship to response to treatment. Clin Cancer Res 1998;4: 1359-1366.
26. Hammel P, Boissier B, Chaumette MT, Piedbois P, Rotman N, Kouyoumdjian JC, Lubin R, Delchier JC, Soussi T: Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 1997;40:356-361.
27. Polge A, Bourgaux JF, Bancel E, Pignodel C, Boyer JC, Poirey S, de Bornier BM, Balmes JL, Bali JP: p53 and follow-up of colorectal cancer. Dig Dis Sci 1998;43:1434-1442.
28. Angelopoulou K, Diamandis EP: Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. Eur J Cancer 1997;33: 115-121.
29. Angelopoulou K, Stratis M, Diamandis EP: Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 1997;70:46-51.